Prothena Corporation PLC
PRTA.OQ- Latest Trade
- trading lower25.75USD
- Change
- -0.2
- % Change
0.77%Negative
- Day Range
- 25.37 - 26.26
- 52-Week Range
- 23.82 - 79.70
As of May 26 2022. Values delayed up to 15 minutes
- Previous Close
- 25.95
- Open
- 25.55
- Volume
- 153,659.00
- 3 Month Average Trading Volume
- 9.19
- Shares Out (Mil)
- 46.81
- Market Cap
- 1,214.62
- Forward P/E
- -9.95
- Dividend Yield
- -99,999.99
Key Statistics
1.75 mean rating - 8 analysts
- P/E Excl. Extra Items (TTM)
- 21.13
- Price To Sales (TTM)
- 6.03
- Price To Book (Quarterly)
- 2.76
- Price To Cash Flow (Per Share TTM)
- 17.74
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- 14.96
- Return On Equity (TTM)
- 14.03
2021 (millions USD)
About Prothena Corporation PLC
Company Information
Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.
Address
77 Sir John Rogersons Quay Block C, Grand Canal DocklandsDUBLIN,
D02 T804
Ireland
Industry
Biotechnology & Drugs
Executive Leadership
- Lars G. Ekman
- Independent Chairman of the Board
- Gene G. Kinney
- President, Chief Executive Officer, Director
- Tran B. Nguyen
- Chief Financial Officer, Chief Strategy Officer
- Brandon S. Smith
- Chief Operating Officer
- Karin L. Walker
- Chief Accounting Officer
- Wagner M. Zago
- Chief Scientific Officer
- Hideki Garren
- Chief Medical Officer
- Carol D. Karp
- Chief Regulatory Officer
- Radhika Tripuraneni
- Chief Development Officer
- Michael J. Malecek
- Chief Legal Officer and Company Secretary
- Paula K. Cobb
- Independent Director
- Richard T. Collier
- Independent Director
- Shane M. Cooke
- Independent Director
- K. Anders O. Harfstrand
- Independent Director
- Oleg Nodelman
- Independent Director
- Sanjiv K. Patel
- Independent Director
- Dennis J. Selkoe
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,846.20 | -- |
| Copper | 779.85 | -- |
| Brent Crude Oil | 114.47 | 0.39%Positive |
| CBOT Soybeans | 1,673.00 | 0.48%Negative |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,978.73 | 0.95%Positive |
| Euro STOXX 50 | 3,677.10 | -- |
| FTSE 100 | 7,522.75 | 0.51%Positive |
| Nikkei 225 | 26,685.71 | 0.03%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes